文献速递前列腺癌

pT2N0R1前列腺癌辅助放疗的长期随访配对队列研究

Long-term Follow-up of a Matched Cohort Study Evaluating the Role of Adjuvant Radiotherapy for Organ-confined Prostate Cancer With a Positive Surgical Margin.
PubMed 文献 · Urology · 2017-08-18

该配对队列研究纳入152例pT2N0R1前列腺癌患者,中位随访20年,比较辅助放疗与未放疗的长期肿瘤学结局。辅助放疗与降低生化复发和局部复发风险相关,但未显著改善远处转移或总生存。

要点

  • 辅助放疗组20年生化复发累积发生率25% vs 未放疗组52%(P<.001)。
  • 辅助放疗组20年局部复发累积发生率3% vs 未放疗组12%(P=.03)。
  • 远处转移和总生存两组无显著差异,复发多呈惰性病程。

核心结论

  • 对于pT2N0R1前列腺癌男性,辅助放疗与降低生化复发和局部复发风险相关,但未显著改善无转移生存或总生存。

研究设计与样本

  • 配对队列研究,纳入1987年至1996年间行根治性前列腺切除加盆腔淋巴结清扫的pT2N0前列腺癌且单一切缘阳性男性。
  • 接受辅助放疗者按年龄、手术年份、Gleason评分、术前前列腺特异性抗原、切缘阳性部位和DNA倍体与未接受辅助放疗者1:1配对。
  • 共纳入152例男性,每组76例,中位随访20年(四分位距19,22)。

主要发现

  • 20年生化复发累积发生率辅助放疗组25% vs 未放疗组52%(P<.001)。
  • 20年局部复发累积发生率辅助放疗组3% vs 未放疗组12%(P=.03)。
  • 20年远处转移累积发生率辅助放疗组10% vs 未放疗组7%(P=.44),无显著差异。
  • 20年总生存概率辅助放疗组56% vs 未放疗组68%(P=.08),无显著差异。
  • 竞争风险模型中,辅助放疗与降低生化复发风险相关(HR=0.40;95%CI 0.23-0.70;P<.001)和降低局部复发风险相关(HR=0.21;95%CI .05-0.98;P=.05),但与远处转移风险无关(HR=1.56;95%CI 0.51-4.75;P=.43)。

临床怎么用

  • 作者结论指出,对于pT2N0R1前列腺癌男性,辅助放疗与降低生化复发和局部复发风险相关,但未显著改善无转移生存或总生存。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate if adjuvant radiation therapy (ART) is associated with improved long-term oncologic outcomes for pT2N0R1 prostate cancer (PCa). METHODS: Men with pT2N0 PCa and a single positive surgical margin following radical prostatectomy and pelvic lymphadenectomy were identified (1987-1996). Men who received ART were matched 1:1 to men who did not receive ART based on age, year of surgery, Gleason score, preoperative prostate-specific antigen, site of positive surgical margin, and DNA ploidy. Biochemical recurrence (BCR), local recurrence, distant metastasis, and overall survival (OS) were compared between groups in time-to-event analyses. RESULTS: The cohort included 152 men (76 per group) with a median follow-up of 20 years (interquartile range 19,22). ART was associated with a lower cumulative incidence of BCR (25% vs 52%; P <.001) and local recurrence (3% vs 12%; P = .03), but no significant differences in cumulative incidence of distant metastasis (10% vs 7%; P = .44) or in probability of OS (56% vs 68%; P = .08) at 20 years. In competing risks models, receipt of ART was associated with reduced risks of BCR (hazard ratio [HR] = 0.40; 95% confidence interval [CI] 0.23-0.70; P <.001) and local recurrence (HR = 0.21; 95% CI .05-0.98; P = .05), but not distant metastasis (HR = 1.56; 95% CI 0.51-4.75; P = .43). In the Cox model, ART was not associated with improved OS (HR = 1.56; 95% CI 0.94-2.57; P = .08). CONCLUSION: ART was associated with reduced risks of BCR and local recurrence for men with pT2N0R1 PCa. However, ART was not significantly associated with metastasis-free or OS benefits, as recurrences in these patients generally followed an indolent trajectory with 20 years of median follow-up.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Bhindi B, Carlson RE, Mason RJ, et al. Long-term Follow-up of a Matched Cohort Study Evaluating the Role of Adjuvant Radiotherapy for Organ-confined Prostate Cancer With a Positive Surgical Margin. Urology. 2017. PMID: 28823636. doi:10.1016/j.urology.2017.06.054

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。